NCT07293884

N- Acetylcysteine in Airway Clearance in Broncheictasis

Efficacy of Nebulized Versus Intravenous N- Acetylcysteine in Airway Clearance in Broncheictasis

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: Assiut University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

It has been deduced that reducing the production of mucus or improving the clearance of sputum in the airway is the key to enhance the therapeutic efficacy for bronchiectasis . Mucoactive drugs are commonly used to clear the airway in mucus hypersecretion diseases. Currently, investigators have found that N-acetylcysteine (NAC), an effective mucolytic agent, not only reduces the viscosity and elasticity of sputum, but it also has anti-inflammatory and antioxidant activity. Additionally, the Spanish guidelines on the treatment of bronchiectasis indicate that the use of N-acetylcysteine should be considered for patients with bronchiectasis and COPD. Therefore, as a classic mucolytic agent with antioxidant and anti-inflammatory properties, N-acetylcysteine can be effective in the treatment of bronchiectasis

Conditions

• Broncheictasis

Interventions

Type	Name	Description
DRUG	N Acetyle cysteine given by IV injection	Arm: IV N Acetyle cysteine
DRUG	Nebulized N Acetyle cysteine	Arm: Nebulized N Acetyle cysteine

Timeline

• Start date: 2025-12-01
• Primary completion: 2026-03-01
• Completion: 2026-04-01
• First posted: 2025-12-19
• Last updated: 2025-12-19